Deletions involving chromosome 9 occur in more than 50% of human bladder cancers of all grades and stages. Most involve loss of the whole chromosome or of an entire chromosome arm but some small deletions are found which can be used to de®ne critical regions which may contain tumour suppressor genes. We have localized such a critical region of deletion at 9q34 between the markers D9S149 and D9S66, an interval which contains the Tuberous Sclerosis gene TSC1. Single strand conformation polymorphism (SSCP) and sequence analysis of TSC1 in bladder tumours and cell lines with 9q34 loss of heterozygosity (LOH) has identi®ed ®ve mutations in retained TSC1 alleles. Our results support the hypothesis that TSC1 can act as a bladder tumour suppressor gene.
Keywords: TSC1; bladder cancer; loss of heterozygosity; 9q34
Molecular and cytogenetic studies have identi®ed a number of chromosomal regions that are often deleted in transitional cell carcinoma (TCC) of the bladder (Knowles, 1998) . Loss of all or part of chromosome 9 is the most common ®nding (450%) in tumours of all grades and stages. Most of these deletions are large, involving the loss of the whole chromosome or chromosome arm. However, small deletions are sometimes found and these can be used to de®ne critical regions of the chromosome which may contain tumour suppressor genes. Four such regions of deletion on chromosome 9 have been previously de®ned in bladder cancer, at 9p21 (Cairns et al., 1994; Devlin et al., 1994) , 9q12-31 (Habuchi et al., 1995; Simoneau et al., 1996) , 9q32-33 (Habuchi et al., 1997) and 9q34 (Habuchi et al., 1995; Orlow et al., 1994; Simoneau et al., 1996) . The results presented here further re®ne the localization of the 9q34 locus.
The region of deletion in 9q34 was previously mapped between the markers D9S61 and D9S67. This interval was de®ned by breakpoints in two tumours, one of which had an interstitial deletion and one a short terminal deletion of chromosome 9 (Habuchi et al., 1995) . To search for additional small deletions in the region, we examined 102 bladder tumours, comprising 53 new samples and 49 cases in which LOH had not been detected at any 9q loci in two previous studies (Habuchi et al., 1995; Keen and Knowles, 1994) and which therefore must contain either no deletions or small deletions on 9q. Seventeen microsatellite markers were selected to give even coverage of 9q34 from D9S61 to the telomere and these were used for LOH analysis. We identi®ed six tumours with deletions only in 9q34 (Figure 1 ), three of which had terminal deletions and three with interstitial deletions. These latter cases provided an indication that deletion in the region is likely to have biological relevance rather than representing random chromosome degradation. The largest of these deletions covers markers separated by 28 cM, while the smallest deletion, in tumour 6, shows LOH of only a single marker, and is at most 3 cM (1.2 Mb) in extent. This 1.2 Mb critical minimum deletion falls within a region for which a complete physical map has previously been constructed, and from which a gene for the autosomal dominant disease Tuberous Sclerosis (TSC) has been isolated (Hornigold et al., 1997; van Slegtenhorst et al., 1997) .
TSC is characterized by the development of hamartomatous growths in multiple organ systems. The gene TSC1 has been demonstrated to be silenced in some TSC hamartomas and so is hypothesized to act as a tumour suppressor (Carbonara et al., 1994; Henske et al., 1996) . It is therefore a candidate for the 9q34 tumour suppressor gene involved in TCC. In contrast to other familial hamartoma syndromes, such as Cowden's disease and von Hippel-Lindau syndrome, malignant tumours are not a common feature of human TSC, although the Eker rat, an animal model of TSC with hemizygous inactivation of TSC2, commonly displays multi-focal carcinomas of kidneys, uterus and spleen. The only cancers reported in TSC are renal tumours, apparently of non-epithelial origin (Pea et al., 1998) , which appear in a small proportion of patients (Bjornsson et al., 1996) . The lack of epithelial pathology and associated malignancy in TSC might argue against its likely involvement in sporadic epithelial cancers. However, there are undoubtedly a number of mechanisms suppressing the onset of malignancy in all the familial hamartoma syndromes and multiple additional genetic events will be required for malignant tumour development. It is noteworthy in this context that Bannayan ± Zonana disease is not associated with an increase in the risk of malignancy, even though the predisposing gene, PTEN, is involved in several types of sporadic cancer. Similarly, the retinoblastoma gene has been shown to contribute to the development of sporadic bladder cancer (Cairns et al., 1991) despite only a very small increase in the incidence of bladder cancer in retinoblastoma families. To examine the involvement of TSC1 in sporadic cancers we have carried out mutation analysis in a series of bladder tumours with deletions at 9q34.
Assuming that both alleles of the target tumour suppressor gene require inactivation for bladder cancer to arise, those tumours with gross deletion of one allele detected as LOH would be predicted to have mutational inactivation of the remaining allele, or transcriptional silencing by other means such as methylation. We therefore carried out single strand conformation polymorphism (SSCP) analysis of TSC1 in ®ve of the six bladder tumours with deletions only in 9q34 (insucient DNA was available for tumour 3) and in 31 bladder tumours with LOH at all loci on 9q, to search for mutations on the retained allele. Fifteen bladder tumour derived cell lines were also analysed, including ®ve which were predicted to have LOH of 9q, based on the presence of only a single allele at multiple 9q loci. Mutation analysis of TSC1 was also carried out on a small panel of DNAs from 15 ovarian tumours which had previously been found to display LOH at multiple loci on 9q.
Primers located within intronic sequences were used to amplify the entire coding sequence of TSC1 in 26 fragments, of 5325 bp each and including all the intron/exon boundaries (Table 1) . PCR products were denatured and separated by electrophoresis in nondenaturing acrylamide gels to resolve the single strand conformers. Nine bands with altered mobility were identi®ed by SSCP analysis in tumour samples and two in cell lines. Bands showing altered mobility were excised from gels, re-ampli®ed and sequenced alongside the same exon ampli®ed from the patient's normal DNA, to determine if the sequence dierence arose de novo in the tumour. Sequencing reactions were carried out using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) and products were separated using an ABI Prism 377 sequencer. The same primers were used for sequencing as had been used in the PCR reactions. Six of the novel bands represented sequence polymorphisms found also in the normal DNA of the individuals concerned. These comprised two in intron 15 (2218+71delAG) and four in exon 22 (C3050T; A943A). Several band shifts were also identi®ed in intron 20, representing at least three polymorphic alleles resulting from length dierences in a poly T stretch. All of these polymorphisms have been described previously in TSC patients Young et al., 1998) . Four mutations were identi®ed in tumours which were not present in the normal DNA of the individuals; one in a tumour with a small deletion in 9q34 (tumour 4) and three in tumours with larger deletions of 9q. One mutation was identi®ed in a cell line (Figure 2) . Four of the tumours with LOH con®ned to 9q34 did not show any altered bands by SSCP. To try to identify mutations in these tumours the entire coding region of TSC1 was sequenced from each tumour. No further mutations were found, but the previously reported polymorphism T1186C was observed in one sample. Homozygous deletion analysis was carried out using duplex PCR reactions containing end-labelled primers for a locus at which a tumour showed LOH and primers for an exon of TSC1. Twenty-three cycles of retention of heterozygosity; loss of heterozygosity; not informative; not done. (b) Examples of LOH. PCR reactions were carried out in a volume of 12.5 ml, containing 5 ng of template DNA, 1 unit of Taq polymerase (Life Technologies) with the manufacturer's buer at the recommended concentration. One primer of each pair was end-labelled using T4 polynucleotide kinase and [g 32 P]dATP. Twenty-seven cycles of PCR were carried out and aliquots were electrophoresed through 6% denaturing polyacrylamide gels. Tumour 5 shows LOH at markers D9S260 and D9S64, with retention at D9S61 and D9S67. Tumour 6 shows LOH at D9S150 only, with retention at D9S149 and D9S66, thus de®ning the minimum critical region of deletion TSC1 mutations in sporadic cancer N Hornigold et al PCR were used. Homozygous deletion of the gene was not detected in the cell lines analysed but cannot be excluded in the tumours due to the presence of some contaminating normal cell DNA in the samples and the lack of a suitable polymorphic marker within the TSC1 gene for use in duplex microsatellite typing. These results show that TSC1 is inactivated by deletion of one allele and mutation of the retained allele in a proportion of TCCs, indicating that this gene is the likely 9q34 target in these sporadic tumours. We have found mutations in 1/5 tumours with LOH con®ned to 9q34, 3/31 tumours with LOH extending across the whole of 9q34 and one of 15 bladder tumour derived cell lines, ®ve of which (including that in which the mutation was found) are predicted to have 9q34 LOH. The ®nding of mutations in primary tumours demonstrates that loss of function of TSC1 contributes to the development of TCC in vivo. All of the mutations were found in bladder tumour derived DNA: DNA from the ovarian tumours showed no mutations. Ovarian tumours show frequent LOH of large regions of 9q and available mapping data is compatible with one or two regions of deletion distal to 9q31, one of which lies telomeric to HXB and includes the TSC1 region (Schultz et al., 1995) . Our ®nding of no mutations may re¯ect a lack of involvement of TSC1 in ovarian cancer or the relatively small size of our tumour panel.
The mutations that we have identi®ed are spread throughout the gene and are of various types (Table 2) . A nonsense mutation in exon 11, a single base deletion causing a frame shift in exon 15 and a mutation of an invariant base at the splice donor site at the 3' end of exon 20 are all predicted to lead to the production of truncated proteins. Also in exon 15 there is an in-frame 21 bp deletion accompanied by an adjacent T to G mutation, which results in the replacement of eight amino acids (576 ± LETSIFTP ± 583) with a single C residue. In exon 4 we have identi®ed a missense mutation (A 424 G) which results in an amino acid change of His?Ala. None of these is identical to any mutation previously published in studies of TSC van Slegtenhorst et al., 1997; Young et al., 1998) . However a number of truncating mutations have been identi®ed in TSC families, including 41 frameshifts (19 of these in exon 15, as identi®ed here), 22 nonsense mutations and three splice site mutations. All are expected to lead to complete or partial ablation of gene function due to the loss of functional domains. Only two missense mutations have been reported in TSC patients, in exons 15 and 17, and there have been no reports of in-frame deletions. In order to result in loss of gene function, such mutations would have to disrupt a critical structural or functional domain. The two non-truncating mutations identi®ed here may therefore identify critical amino acid residues. The reason for the relatively high frequency of such mutations in our small sample is not clear but may be due to chance or may re¯ect real dierences in the type of mutation which can participate in a familial and somatic context.
Most bladder tumours with chromosome 9 LOH show loss of an entire copy of the chromosome. However, in any individual tumour, inactivation of all relevant genes may not be present. Thus validation of chromosome 9 tumour suppressors in bladder cancer presents some diculties compared with the situation where only one suppressor locus is TSC1/5F  TSC1/5R  TSC1/6F  TSC1/6R  TSC1/7F  TSC1/7R  TSC1/8F  TSC1/8R  TSC1/9F  TSC1/9R  TSC1/10F  TSC1/10R  TSC1/11F  TSC1/11R  TSC1/12F  TSC1/12R  TSC1/13F  TSC1/13R  TSC1/14F  TSC1/14R  TSC1/15aF  TSC1/15aR  TSC1/15bF  TSC1/15bR  TSC1/15cF  TSC1/15cR  TSC1/16F  TSC1/16R  TSC1/17F  TSC1/17R  TSC1/18F  TSC1/18R  TSC1/19F  TSC1/19R  TSC1/20F  TSC1/20R  TSC1/21aF  TSC1/21aR  TSC1/21bF  TSC1/21bR  TSC1/22F  TSC1/22R  TSC1/23aF  TSC1/23aR  TSC1/23bF  TSC1/23bR  TSC1/23cF  TSC1/23cR   GGGGCCATTTAGTGACTGT  GCAGGATTCTAGTGGCTCTAA  TAGGATGTTAAGGGGAATAAGT  CTCAGGACAAGTTGCACAGT  TGCTGTCTTTATTTGTGTTAACTTC  CATAAAACCATTTCATTCAAATC  GTGCCAGTGCCTGACAGAC  ATCAATAATGAAAGCATTCACCTC  TGTTTTGCACTCCTCAATCTG  GGTATAAATGCAGCCTATCTAAACAG  ATTCAGCCCTTTATAATTTGTCAAC  CTCCTAGATCACATTTTCAATCTCTC  TTGATTACAGTTTGCATTTCTTGAC  CCAGAGACAAAGTTGCAAAACAG  CCTAAAACCACACACTAACCCC  AAAGCAGAGGAGAGAGCAGG  TGACTTAGCATTCCTTTGCCAC  AAGGCAGGCCAAAACCAAC  TGTTCTGCCCTTGTCTCTAAG  AGTGAGTCACTGTGCCTGG  GCAACATTTTTCGTCTTGTG  CCAATTAGAAGAGGCAAGC  CTTTGACTTCAGTTGTCTTTGTTTC  GCAATCCCACATACATTACCTTC  GAATACCGACTGCCATTTCT  AGGGCTTTCATCAGCACTG  GCAAGCCTTTACTCCCATAG  GGCACACCATCTTCCTCTG  CAGCCCATCATTTTGTCATC  AGGTGGGAGTGTGAAGAATG  CGTTTTTTTCTTGGTAAGATCG  TGGATTTGGAGCTAAAGTAACAAC  AAAGGCATTTCTGCCACCC  TCATGCTGACCCAAAACAAAAC  TCGCAGTGTGTGTTAAATTGCC  ACTGACTGCCTCCCTCCCC  CCTCAAACTTCATGTCCACG  ACCTGTCTGAAGGAAGAATGTTAG  TTTATGTCGTCGGATTTTTCAC  ACTGTCTGGGTCTGAAACGC  CTAGGATAATACTACCAGCT  TTCTAGCTCTTTCCGATAGG  TTCAGGAAGTAGAAATGATGA  AGATACAGACCAGCCAGAAT  TCAAACTCCAGGCAAGGTAA  CAGCTTAGTCCCAAGGTCAT  CCTCCGAATGTGGACAGTC  CAGACGCTTCTCCCATAGTC  GGCAGTAGTGGAAGCAGAGG  CCAAGTCTTTGCCCAGTTCT  CATGACCAGTAGCCTTTCTGA predicted within a deleted region. It is not possible therefore to predict the expected frequency of TSC1 mutation in tumours with large deletions. However, it was expected that, if TSC1 is the target gene and assuming a two-hit mechanism of gene inactivation, mutations should be found in all those tumours with LOH con®ned to 9q34. This was not the case. There are a number of possible explanations for this observation. We considered the possibility that our SSCP technique might be suboptimal. To test this we carried out SSCP on a panel of 20 DNAs from familial cases of TSC for which the inactivating mutation was known (provided by Professor Sue Povey). Clear bandshifts were seen in 18/20 samples (data not shown) indicating that it is unlikely that large numbers of mutations have been missed due to inadequate screening technique. Another possibility is that TSC1 is inactivated in tumours by changes in non-coding regions of the gene. The genomic sequence of the region upstream of TSC1 shows a large CpG island at the 5' end of the gene (*1.2 kb long and 66% GC content). This region might be aected by mutations, or transcriptional silencing may be brought about by aberrant methylation, as has been demonstrated for other tumour suppressors (Baylin et al., 1998) . Both of these possibilities need to be examined. Not all TSC hamartomas show LOH in the region of the causative locus and haploinsuciency without the requirement for a second hit has been proposed to explain this observation . It is possible that TSC1 haploinsuciency could also contribute to the TCC phenotype. Finally, it is possible that there is another tumour suppressor gene in the critical region of 9q34. This is a gene-rich part of the genome and contains a number of known genes that have not been evaluated as potential tumour suppressor genes and many expressed sequence tags (ESTs) from genes which have not yet been characterized . The function of the TSC1 gene product, and the physiological pathways through which it acts have not yet been elucidated. It is known that it binds to the TSC2 gene product, probably through coiled-coil domains and that it localizes to as yet uncharacterized structures within the cytoplasm (van Slegtenhorst et al., 1998) . The TSC2 gene product has been reported to have a GTPase activating protein (GAP) domain and transcription activation domains and has been shown to be a modulator of RXR mediated transcription (Henry et al., 1998) suggesting a role in the regulation of cellular dierentiation. Two other observations that have previously been made suggest possible areas where the TSC1 gene product may function. Pajak et al. (1997) carried out whole embryo cultures of rats carrying homozygous mutations of TSC2 and found that cardiomyocytes in these cultures failed to withdraw from the cell cycle, and Soucek et al. (1997) have shown that anti-sense oligonucleotide inhibition of TSC2 induces G0 cells to re-enter the cell cycle and not undergo arrest after serum withdrawal. Ishibashi et al. (1991) showed that cells cultured from TSC lesions displayed a high incidence of abnormal metaphases, which led to chromosomal instability in these cells. Scappaticci et al. (1988) con®rmed this observation and found a low level of chromosomal abnormality in uncultured cells from TSC patients. Either, or both, of these cellular phenotypes, i.e. failure to withdraw from cell cycle and chromosomal instability, are likely to be important in tumorigenesis. showing bandshifts caused by TSC1 mutations in bladder tumours. PCR was carried out on 10 ng of tumour DNA, using AmpliTaq Gold polymerase (Perkin Elmer) in the manufacturer's recommended conditions. Products were separated in 0.56MDE (Flowgen) gels at room temperature and in 6% polyacrylamide (99 : 1 acrylamide:bis-acrylamide) gels at 48C. PCR products from tumour DNA (T) have been run alongside products from normal DNA isolated from peripheral lymphocytes from the same individuals (N). PCR products from cell line DNA have been run alongside unrelated normal DNA Abbreviations TCC, transitional cell carcinoma; LOH, loss of heterozygosity; SSCP, single strand conformation polymorphism; TSC, tuberous sclerosis complex.
